Does Pulse-triggered VNS Autostimulation Increase VNS Efficacy

Epilepsy Clinical Trial

— ERAS  

Official title:

Does Additional ECG-triggered Stimulation Increase the Efficacy of Vagus Nerve Stimulation? An Investigator-initiated Prospective, Multinational, Single Blinded, Randomized Cross-over Trial in Patients With VNS-treatment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04095247
• Other study ID #: 2018/667
• Status: Terminated
• Start date: April 3, 2018
• Est. completion date: April 6, 2022

Study information

• Verified date: October 2023
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a research study to investigate whether the use of an extra function of vagus nerve stimulator (VNS) can give an improved effect against epilepsy. Many epileptic seizures are accompanied by an increase in heart rate. One auxiliary function of a new type of stimulator is continuous measurement of cardiac activity, and when pulse rate increases an extra stimulation is delivered. It has been shown that this can interrupt attacks that are about to develop. In this project the investigators will test how well that works for patients in daily life. The new type of stimulator has similar design and location as the old one. Patients who have already been treated with VNS and who need to switch the stimulator because the battery is starting to run out, are asked whether they want to participate. The study is a randomized and blinded cross-over. The activation of the extra feature is done either in the first or the second treatment phase. Which phase is the phase with activated autostimulation will be decided by random selection and the patient does not know when the auxiliary function is started. The study period is 11 months. Patients are asked to fill in some questionnaires on seizures, quality of life and quality of sleep.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: April 6, 2022
• Est. primary completion date: April 6, 2022
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Subjects, 12 years of age or older, who have a VNS without ECG-triggered auto stimulation implanted, have a positive effect and have a device replacement with model 106 or model 1000 due to low battery capacity,.
• Subjects, who have 2 or more seizure per month and not more than 28 days between seizures during the baseline.
• Subjects, who are on a stable regiment of antiepileptic drug treatment for at least 3 month prior to enrollment and maintain on this regimen throughout the study.
• VNS parameters have not been changed I the last 3 month prior to enrollment.
• Subjects which are using an off time of at least 1.8 min. (If the patient is on a duty cycle involving an off-time of 1.1 min. or less, and willing to participate in the study the duty cycle will have to be changed to fulfill the inclusion criteria as follows. The off-time will be changed to 1.8 min. and the on-time accordingly to achieve about the same duty cycle as the patient had before. If the duty cycle is above 30% the parameters will be changed to 60 sec./1.8 min., if the duty cycle is between 30% and 23% the parameters will be change to 30 sec./1,8 min., if the duty cycle is 20% the parameters will be change to 21 sec./1,8 min. and if the duty cycle is 15% the parameters will be change to 14 sec./1,8 min. After at periode of 3 month observation the patient can be included in the study.)
• Either the subjects or the legal guardian are able to agree to participate by signing the informed consent form.

Exclusion Criteria:

• Subjects with rapidly progressive neurodegenerative or rapidly progressing neoplastic disease.
• Subjects or legal guardians who are unable to understand the study procedures.

Related Conditions & MeSH terms

• Epilepsy

Intervention

Device:
• Vagus nerv stimulator
pulse triggered autostimulation

Locations

Country	Name	City	State
Norway	Norwegian epilepsy center	Oslo

Sponsors (5)

Lead Sponsor	Collaborator
Oslo University Hospital	Filadelfia Epilepsy Hospital, Rigshospitalet, Denmark, Tampere University Hospital, Universitaire Ziekenhuizen KU Leuven

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects with >25 % change in seizure frequency	Percentage of subjects with >25 % change in seizure frequency	after 11 month
Secondary	Change in mean National Hospital Seizure Severity Scale score	Change in mean National Hospital Seizure Severity Scale score (range 1-22 Points, higher values indicate a worse situation)	after 11 month
Secondary	Change in mean average seizure duration	Change in mean average seizure duration	after 11 month